276 related articles for article (PubMed ID: 24040940)
1. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
2. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
3. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
[TBL] [Abstract][Full Text] [Related]
4. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
8. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D
Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276
[TBL] [Abstract][Full Text] [Related]
9. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
10. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
14. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
[TBL] [Abstract][Full Text] [Related]
16. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
18. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
19. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
20. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
